Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

PARP7 inhibitor BY101921

An orally available inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) 7, with potential immunomodulating and antineoplastic activities. Upon oral administration, PARP7 inhibitor BY101921 targets, binds to, and inhibits the activity of PARP7, which restores type I interferon (IFN) signaling. This may lead to the induction of both innate and adaptive immune responses, and the inhibition of tumor growth and proliferation. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:BY 101921
BY-101921
BY101921
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search